Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …

Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic
cells driven by somatic gene mutations. Although assessment of morphology plays a crucial …

Background Polycythemia vera is a chronic myeloproliferative neoplasm characterized by
erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory …

PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/
hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

A group of international experts, including hematopathologists, oncologists, and geneticists
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …

The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera
(PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and …

The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a
heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera …

Background There is no evidence that phlebotomy alone is sufficient to steadily maintain
haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to …